Mark Poznansky, MD, PhD, is a professor of medicine at Harvard Medical School, an attending physician in infectious diseases medicine at the Massachusetts General Hospital (MGH), and Director of the Vaccine and Immunotherapy Center (VIC) at MGH. He holds a doctoral degree from Cambridge University and a medical degree from University of Edinburgh. Dr. Poznansky was also named a MGH Research Scholar. His clinical subspecialization includes the treatment of infection in immune-compromised patients.
The scientific teams at VIC work at the interface between scientific discovery and medical product development, discovering novel immune processes, defining their molecular mechanisms and exploring their relevance to the development of vaccines and immunotherapies for cancer, infectious diseases, type I diabetes and neurodegenerative diseases including ALS. VIC’s research and development work has been continuously funded by the National Institutes of Health, the Department of Defense, Juvenile Diabetes Research Foundation (JDRF), and other private foundations over the past 13 years.
Dr. Poznansky brings his passion and wealth of personal experience of medical discovery, translational medicine and the development of novel products for patients to his work. He has generated a portfolio of patents at the MGH, most of which are licensed to industry or developed in partnership with private and federal organizations, including DARPA. He is also the scientific founder of Celtaxsys, ACTx, VICapsys, Aperisys, Voltron Therapeutics and PDTx. Dr. Poznansky also served on the Innovation Liaison Program at MGH, working at the interface between inventive scientists at MGH and the Mass General Brigham Ventures and Licensing Office. Dr. Poznansky is committed to training the next generation of innovative scientists and serves as a mentor for high school, undergraduate, graduate students at MGH in the Summer Research Training Program at MGH, the Boston Scientific Careers Program and at Clare College, Boston University Academy, Cambridge University and Imperial College in England.Back to Commercialization Council